[go: up one dir, main page]

MXPA02006167A - Survivin promotion of angiogenesis. - Google Patents

Survivin promotion of angiogenesis.

Info

Publication number
MXPA02006167A
MXPA02006167A MXPA02006167A MXPA02006167A MXPA02006167A MX PA02006167 A MXPA02006167 A MX PA02006167A MX PA02006167 A MXPA02006167 A MX PA02006167A MX PA02006167 A MXPA02006167 A MX PA02006167A MX PA02006167 A MXPA02006167 A MX PA02006167A
Authority
MX
Mexico
Prior art keywords
survivin
angiogenesis
promotion
andor
expression
Prior art date
Application number
MXPA02006167A
Other languages
Spanish (es)
Inventor
Dario C Altieria
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of MXPA02006167A publication Critical patent/MXPA02006167A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention discloses methods for promoting angiogenesis using agents that increase the activity function andor expression of survivin. The present invention also discloses methods for inhibiting angiogenesis using agents that inhibit activity, the function andor expression of survivin.
MXPA02006167A 1999-12-21 2000-12-21 Survivin promotion of angiogenesis. MXPA02006167A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17299199P 1999-12-21 1999-12-21
PCT/US2000/034663 WO2001046455A2 (en) 1999-12-21 2000-12-21 Survivin promotion of angiogenesis

Publications (1)

Publication Number Publication Date
MXPA02006167A true MXPA02006167A (en) 2004-02-26

Family

ID=22630045

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02006167A MXPA02006167A (en) 1999-12-21 2000-12-21 Survivin promotion of angiogenesis.

Country Status (6)

Country Link
EP (1) EP1242050A4 (en)
JP (1) JP2003529554A (en)
AU (1) AU2730801A (en)
CA (1) CA2393646A1 (en)
MX (1) MXPA02006167A (en)
WO (1) WO2001046455A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900187B2 (en) 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
WO2000049937A2 (en) 1999-02-26 2000-08-31 The University Of British Columbia Trpm-2 antisense therapy
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
WO2002007732A2 (en) * 2000-07-26 2002-01-31 Cambridge University Technical Services Limited Use of panaxatriol for stimulation angiogenesis
EP1465995B1 (en) 2002-01-17 2008-07-30 The University of British Columbia Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
WO2004018675A1 (en) 2002-08-21 2004-03-04 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
US7713738B2 (en) 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
EP1615943A4 (en) * 2003-04-18 2006-08-16 Univ Pennsylvania COMPOSITIONS AND METHODS FOR INHIBITING ARNIC OF ANGIOPOIETIN 1 AND 2 AND THEIR TIE2 RECEPTOR
US8710020B2 (en) 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
BRPI0517613A (en) 2004-11-09 2008-10-14 Santaris Pharma As oligonucleotides lna and cancer treatment
WO2009043104A1 (en) * 2007-10-04 2009-04-09 Bionomics Limited Markers of endothelial cells and uses thereof
FR2932086A1 (en) * 2008-06-06 2009-12-11 Lvmh Rech ANTI-AGE COSMETIC CARE METHOD BY STIMULATING THE EXPRESSION OF SURVIVAL
KR101802626B1 (en) 2013-03-15 2017-11-28 아이리스 인터내셔널 인크. Method and composition for staining and sample processing
AU2016318158B2 (en) * 2015-09-04 2022-09-15 Health Research, Inc. Anti-survivin antibodies for cancer therapy

Also Published As

Publication number Publication date
EP1242050A2 (en) 2002-09-25
EP1242050A4 (en) 2004-05-26
CA2393646A1 (en) 2001-06-28
WO2001046455A2 (en) 2001-06-28
JP2003529554A (en) 2003-10-07
WO2001046455A3 (en) 2002-05-10
AU2730801A (en) 2001-07-03

Similar Documents

Publication Publication Date Title
PL319605A1 (en) Novel benzoxazoles
MXPA02006167A (en) Survivin promotion of angiogenesis.
TR200000782T2 (en) Resorcinol derivatives.
MY126559A (en) Fungicidal 2-methoxybenzophenones
DE69526790D1 (en) COMPOUNDS TO INHIBIT PHOSPHODIESRERASE IV
EP1208085A4 (en) Benzanilides as potassium channel openers
ATE365799T1 (en) FACTOR IX/FACTOR IXA ACTIVATE ANTIBODIES
BG105009A (en) Method for producing 4-carboxyamino-2-substituted 1,2,3,4-tetrahydroquinoline
MA24643A1 (en) SUBSTITUTED TETRAHYDRO-NAPHTHALENES AND SIMILAR COMPOUNDS
NO993350L (en) Vitronectin receptor antagonists
ATE293691T1 (en) MYOSTATIN GENE PROMOTER AND INHIBITION OF ITS ACTIVATION
PL374080A1 (en) Processes for the preparation of fibrinogen
EA200200545A1 (en) ONCOLYTIC COMBINATIONS FOR CANCER TREATMENT
AP2001002220A0 (en) Calcilytic compounds.
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
TR199901017A2 (en) Insecticide composition.
NO985002D0 (en) Reception procedure as well as recipient
WO1998046632A3 (en) Inhibitors for urokinase receptor
MXPA05003315A (en) Controlled releases system containing temozolomide.
MXPA03010498A (en) Process for the preparation of imipenem.
GB9924941D0 (en) Treatment of dyskinesia
ZA200107985B (en) Substituted benzimidazole, the production thereof and the use thereof as means against parasitic protozoa.
PT1339398E (en) Treatment of motor fluctuations with 5-hydroxytryptamine 1a receptor activity enhancing compounds
DE60000826D1 (en) 14.BETA., 17-ALPHA-HYDROXYMETHYLANDROSTAN DERIVATIVES AS ANDROGENES
EP1011329A4 (en) 7-methylthiooxomethyl and 7-methylthiodioxomethyl paclitaxels